Regulatory Approval/Market LaunchFormycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM (ustekinumab-aauz) 30.09.2024 / 07:30 CET/CESTThe issuer is solely responsible for the content of ...
In rheumatoid arthritis (RA), the identification of prognostic factors (PF) capable of predicting disease outcome, response to treatment or success of dose reduction is an important issue, as these ...
Currently there are no cures for rheumatoid arthritis (RA) which affects 40,000 people in Ireland. The disease costs an estimated €20,000 per patient, per year with an overall cost to the health ...